Revolution Medicines Announces Key Leadership Additions, including Alan Sandler, M.D. as Chief Development Officer
Revolution Medicines Shares New Clinical Results Supporting Initiation of RASolute 303, a Global Phase 3 Registrational Trial of Daraxonrasib in First Line Metastatic Pancreatic Ductal Adenocarcinoma
Standard Uranium Executes Definitive Agreement to Option Rocas Uranium Project and Initiates Inaugural Exploration Program
Blue Sky Uranium Launches Exploration Program after Completing Ivana Deposit Infill Drilling Program and Advances towards Prefeasibility Study at Amarillo Grande Project, Argentina
